Interleukin-33 Potentiates Bleomycin-Induced Lung Injury
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The mechanisms of interstitial lung disease (ILD) remain incompletely understood, although recent observations have suggested an important contribution by IL-33. Substantial elevations in IL-33 expression were found in the lungs of patients with idiopathic pulmonary fibrosis and scleroderma lung disease, as well as in the bleomycin injury mouse model. Most of the observed IL-33 expression was intracellular and intranuclear, suggesting involvement of the full-length (fl) protein, but not of the proteolytically processed mature IL-33 cytokine. The effects of flIL-33 on mouse lungs were assessed independently and in combination with bleomycin injury, using recombinant adenovirus–mediated gene delivery. Bleomycin-induced changes were not affected by gene deficiency of the IL-33 receptor T1/ST2. Combined flIL-33 expression and bleomycin injury exerted a synergistic effect on pulmonary lymphocyte and collagen accumulation, which could be explained by synergistic regulation of the cytokines transforming growth factor–β, IL-6, monocyte chemotactic protein–1, macrophage inflammatory protein\x{2013}1α, and tumor necrosis factor-α. By contrast, no increase in the levels of the Th2 cytokines IL-4, IL-5, or IL-13 was evident. Moreover, flIL-33 was found to increase the expression of several heat shock proteins (HSPs) significantly, and in particular HSP70, which is known to be associated with ILD. Thus, flIL-33 is a synergistic proinflammatory and profibrotic regulator that acts by stimulating the expression of several non-Th2 cytokines, and activates the expression of HSP70.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765 · cited 1×
“In patients with scleroderma or systemic sclerosis (SSc), scleroderma lung disease (SLD) is the leading cause of death (1, 2), whereas patients with IPF live an average of only 2–3 years after diagnosis (3).”
BackgroundThe IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1
Cayrol, C., & Girard, J.-P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812690106 · Cited by 707
Suppression of Interleukin-33 Bioactivity through Proteolysis by Apoptotic Caspases
Lüthi, A. U., Cullen, S. P., McNeela, E. A., Duriez, P. J., Afonina, I. S., Sheridan, C., Brumatti, G., Taylor, R. C., Kersse, K., Vandenabeele, P., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.05.007 · Cited by 677
Kahloon, R. A., Xue, J., Bhargava, A., Csizmadia, E., Otterbein, L., Kass, D. J., Bon, J., Soejima, M., Levesque, M. C., Lindell, K. O., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0506oc · Cited by 190
Roles of T lymphocytes in pulmonary fibrosis
Luzina, I. G., Todd, N. W., Iacono, A. T., & Atamas, S. P. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0707504 · Cited by 163 · cited 3×
“IL-33–expressing cells were abundant in the inflammatory infiltrates (see Figure E1 in the online supplement), which are known to consist mostly of lymphocytes, whereas only occasional macrophages, neutrophils, and eosinophils are present in the pulmonary infiltrates of these patients (7, 29, 31, 33, 35, 45).”
BackgroundSelf-citationMechanisms of Oncostatin M-Induced Pulmonary Inflammation and Fibrosis
Mozaffarian, A., Brewer, A. W., Trueblood, E. S., Luzina, I. G., Todd, N. W., Atamas, S. P., & Arnett, H. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.7243 · Cited by 153
Self-citation
Cited by
Interleukin-33 in health and disease
Liew, F. Y., Girard, J.-P., & Turnquist, H. R. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.95 · Cited by 1,147
Pathogenic Mechanisms Underlying Idiopathic Pulmonary Fibrosis
Moss, B. J., Ryter, S. W., & Rosas, I. O. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042320-030240 · Cited by 821
Biomaterials: Foreign Bodies or Tuners for the Immune Response?
Mariani, E., Lisignoli, G., Borzì, R. M., & Pulsatelli, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030636 · Cited by 706
“The emerging links between IL-33 and fibrotic disorders [332,333] might suggest that the release of IL-33 at the biomaterial implantation site may induce collagen deposition.”
BackgroundLi, D., Guabiraba, R., Besnard, A.-G., Komai-Koma, M., Jabir, M. S., Zhang, L., Graham, G. J., Kurowska-Stolarska, M., Liew, F. Y., McSharry, C., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.05.011 · Cited by 413
Pulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease?
Byrne, A. J., Maher, T. M., & Lloyd, C. M. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.02.004 · Cited by 315
Metadata
- Authors
- Luzina, I. G., Kopach, P., Lockatell, V., Kang, P. H., Nagarsekar, A., Burke, A. P., Hasday, J. D., Todd, N. W., & Atamas, S. P.
- Venue
- American Journal of Respiratory Cell and Molecular Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-12-01
- Volume
- 49
- Issue
- 6
- Pages
- 999-1008
- ISSN
- 1044-1549 (ISSN-L)
- 1535-4989
- OpenAlex
- W2001785829
- Cited by
- 120
- References
- 6
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interleukin-33 Potentiates Bleomycin-Induced Lung Injury. https://app.cochat.ai/papers/10.1165/rcmb.2013-0093oc
- The paper
- Luzina, I. G., Kopach, P., Lockatell, V., Kang, P. H., Nagarsekar, A., Burke, A. P., Hasday, J. D., Todd, N. W., & Atamas, S. P. (2013). Interleukin-33 Potentiates Bleomycin-Induced Lung Injury. American Journal of Respiratory Cell and Molecular Biology. https://doi.org/10.1165/rcmb.2013-0093oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.